Rome, 6 Novembre 2025
Artificial lntelligence (Al) is rapidly changing Medicine, especially oncology. lt offers groundbreaking tools to optimize clinical trial design, improve patient selection, accelerate fact collection from real-world data, increase clinical experimentation efficiency, and maximize the use of innovative pharmacological treatments, such as immunotherapy and targeted therapy. The event promises to explore the potential of Al in oncological clinical research with a multidisciplinary and clinical-praxis-oriented approach.
THE FOLLOWING SPECIFIC OBJECTIVES WILL BE DISCUSSED:
- Innovative clinical trial design
New experimental models will be explained, including adaptive studies,
"umbrella" and "basket trials, as well as the use of synthetic arms and RWD (real-world data) data, to make studies more agile, efficient, and less costly.
- Clinical Trial Matching boosted by IA
Al can automatically select patients eligible for studies. Therefore, Al can enhance equity in accessing and efficiency in recruiting, even in complex, personalized trials.
- AI-driven biomarkers and validation
The integration of Al-based predictive biomarkers derived from genomic,
clinical, and radiomic data will be discussed, focusing on the level of validation required for their adoption in regulatory and clinical settings.
- Ethics, biases, and legal framework in AI
A proper use of Al requires great attention to algorithmic biases, discrepancies in its access, and ethical responsibilities. European regulatory principles and implications for Al-assisted trials will be presented.
- From validation to clinical implementation
Lastly, strategies to efficiently validate and integrate Al models in therapeutic planning and in everyday oncological praxis will be examined.